Annovis Bio
ANVS
24 hedge funds and large institutions have $11.9M invested in Annovis Bio in 2022 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 10 closing their positions.
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
2.88% less ownership
Funds ownership: 13.78% → 10.9% (-2.9%)
25% less funds holding
Funds holding: 32 → 24 (-8)
39% less capital invested
Capital invested by funds: $19.6M → $11.9M (-$7.75M)
80% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$192K |
| 2 |
Renaissance Technologies
New York
|
+$183K |
| 3 |
SIAP
Sterling Investment Advisors (Pennsylvania)
Berwyn,
Pennsylvania
|
+$65K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$15.6K |
| 5 |
EL
Essex LLC
Deer Park,
Illinois
|
+$14.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$1.04M |
| 2 |
Two Sigma Investments
New York
|
-$910K |
| 3 |
Morgan Stanley
New York
|
-$649K |
| 4 |
Voloridge Investment Management
Jupiter,
Florida
|
-$406K |
| 5 |
BAM
Blueshift Asset Management
Red Bank,
New Jersey
|
-$289K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Voloridge Investment Management
Jupiter,
Florida
| – | -$406K | -23,116 | Closed |
|
|
BAM
27
Blueshift Asset Management
Red Bank,
New Jersey
| – | -$289K | -16,418 | Closed |
|
|
CSS
28
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$206K | -11,743 | Closed |
|
29
Goldman Sachs
New York
| – | -$181K | -10,273 | Closed |
|
30
UBS Group
Zurich,
Switzerland
| – | -$44K | -2,481 | Closed |
|
31
Marshall Wace
London,
United Kingdom
| – | -$29K | -1,679 | Closed |
|
|
TRCT
32
Tower Research Capital (TRC)
New York
| – | -$12K | -669 | Closed |
|
ANVS Hedge Fund Activity: Q1 2022 in Review
24 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Annovis Bio (ANVS) for Q1 2022, worth a combined $11.9M — down 39% from $19.6M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of ANVS and 2 opened new positions — a net loss of 8 holders — while 7 trimmed existing stakes and 8 added.
The largest buyer was Vanguard Group, adding an estimated $192K. The largest seller was Citadel Advisors, exiting entirely with an estimated $1.04M sold.
- 24 institutional investors held Annovis Bio (ANVS) as of Q1 2022, down from 32 in Q4 2021.
- Funds reported $11.9M of Annovis Bio stock for Q1 2022, down 39% quarter-over-quarter.
- 2 funds opened new Annovis Bio positions in Q1 2022 and 10 closed out, a net change of -8 holders.
- The largest Annovis Bio buyer in Q1 2022 was Vanguard Group, an estimated $192K added.
- The largest Annovis Bio seller in Q1 2022 was Citadel Advisors, an estimated $1.04M sold.
Based on aggregated 13F filings for Q1 2022.